Artelo Biosciences, Inc. (NASDAQ:ARTL) Stock Short Interest Rises 104.7%Defense World · Oct 16, 2026
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor PlatformGlobeNewsWire · Oct 7, 2026
Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Shorted: Short Interest Down 37.2% in SeptemberDefense World · Oct 1, 2026
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical FindingsGlobeNewsWire · Sep 23, 2026
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of ObesityGlobeNewsWire · Sep 16, 2026
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 36.9% in AugustDefense World · Aug 31, 2026Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$6.48 | -$8.01 | Miss |
| May 14, 2026 | -$0.78 | -$4.00 | Miss |
| Feb 24, 2026 | -$4.71 | -$6.66 | Miss |
| Nov 12, 2025 | -$2.46 | -$11.91 | Miss |
| Aug 12, 2025 | -$12.57 | -$16.83 | Miss |
| May 13, 2025 | -$2.40 | -$12.96 | Miss |